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Abstract
We consider two problems that are attracting increasing attention in clinical dose
nding studies. First, we assess the similarity of two non-linear regression models
for two non-overlapping subgroups of patients over a restricted covariate space. To
this end, we derive a condence interval for the maximum dierence between the two
given models. If this condence interval excludes the equivalence margins, similarity
of dose response can be claimed. Second, we address the problem of demonstrating
the similarity of two target doses for two non-overlapping subgroups, using again a
condence interval based approach. We illustrate the proposed methods with a real
case study and investigate their operating characteristics (coverage probabilities, Type
I error rates, power) via simulation.
Keywords and Phrases: equivalence testing, multiregional trial, target dose estimation, sub-
group analyses
1
1 Introduction
Establishing dose response and selecting optimal dosing regimens is a fundamental step in
the investigation of any new compound, be it a medicinal drug, an herbicide or fertilizer,
a molecular entity, an environmental toxin, or an industrial chemical (1). This has been
recognized for many years, especially in the drug development area, where patients are
exposed to a medicinal drug once it has been released on the market (2). An indication
of the importance of properly conducted dose response studies is the early publication of
the tripartite ICH E4 guideline, which gives recommendations on the design and conduct of
studies to assess the relationship between doses, blood levels and clinical response throughout
the clinical development of a new drug (3).
Very often clinical trials are analyzed beyond the primary study objectives by assessing
ecacy and safety proles in clinically relevant subgroups, such as dierent gender, age
classes, grades of disease severity, etc. A rising area of particular importance are global
clinical trials, which are run in dierent countries and potentially serve dierent submissions.
For example, many pharmaceutical companies focus on running global clinical trials that
include a major Japanese subpopulation for later regulatory submission in Japan. A natural
question is then whether the dose response results for the Japanese and the non-Japanese
populations are consistent (4; 5).
To illustrate the general problem, assume that we are interested in assessing similarity
for (a) two dose response curves or for (b) two same target doses, say for male/female or
Japanese/non-Japanese patients. For question (a) we thus want to show that the maximum
dierence in response between two (potentially dierent) non-linear parametric regression
models is smaller than a pre-specied margin. Figure 1a displays an example, where the two
dose response curves follow an Emax and a logistic model. The maximum response dierence
over the dose range is indicated by the arrow. For question (b) we want to show that two
same target doses do not dier relevantly. Figure 1b displays the minimum eective dose
(MED) derived from the two previous dose response models. Here, the MED is dened as
the smallest dose which demonstrates a clinically relevant benet over placebo, as indicated
by the horizontal line in Figure 1b. If we succeed in demonstrating either (a) or (b), evidence
is provided that the dierence in response over the entire dose range under investigation
or the two target doses dier at most marginally. In practice, such a result may provide
sucient evidence that the same dose can be administered in both subgroups (i.e., the doses
for males/females or Japanese/non-Japanese patients are the same).
Demonstrating similarity of target doses or dose response curves in each of several subgroups
has not been addressed in much detail so far in the literature. One exception is (6), who
proposed a non-standard bootstrap approach for question (a) which addresses the specic
form of the interval hypotheses. In particular, data has to be generated under the null
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Figure 1: Assessing similarity for (a) two dose response curves and (b) two same target doses.
hypothesis using constrained least squares estimates. In this paper we consider dierent
methods to address both questions (a) and (b). In Section 2 we address problem (a) using
the results from (7) and derive a condence interval for the maximum dierence between
the two given non-linear regression models over the entire covariate space of interest. If
this condence interval excludes the equivalence margins, similarity of dose response can be
claimed. In Section 3, we consider asymptotic methods to derive condence intervals for the
dierence between two same target doses to address problem (b). Again, if such a condence
interval excludes a pre-specied relevance margin, similarity in dose can be claimed. In
Section 4 we provide some concluding remarks. Technical details are left for the Appendix.
2 Assessing similarity of two dose response curves
We consider the non-linear regression models
Y`;i;j = m`(#`; d`;i) + "`;i;j ; j = 1; : : : ; n`;i; i = 1; : : : ; k`; ` = 1; 2; d`;i 2 D; (1)
where Y`;i;j denotes the jth observed response at the ith dose level d`;i under the `th dose
response model m`. The error terms "`;i;j are assumed to be independent and identically
distributed with expectation 0 and variance 2` . Further, n` =
Pk`
i=1 n`;i denotes the sample
size in group ` where we assume n`;i observations in the ith dose level (i = 1; : : : k`; ` = 1; 2).
We further assume that for both regression models the dierent dose levels are attained
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on the same (restricted) covariate region D. For the purpose of this paper, we assume
D to be the dose range under investigation, although the results in this section can be
generalized to include other covariates. The functions m1 and m2 in (1) denote the (non-
linear) regression models with xed but unknown p1- and p2-dimensional parameter vectors
#1 and #2, respectively. Note that both the regression modelsm1 andm2 and the parameters
#1 and #2 may be dierent. In particular, the design matrices for the two regression models
may be unequal. This implies that we do not assume the same doses to be investigated for
` = 1; 2 and that the sample sizes n` can be unequal. We refer to (8) for an overview of
several linear and non-linear regression models commonly employed in clinical studies.
2.1 Methodology
Using results from (7), we derive in the following a condence interval for the maximum
absolute absolute dierence between the two given non-linear regression models m1 and m2
over the entire covariate space D. We use this condence interval in order to derive a test
demonstrating similarity of the two dose response curves.
Let U (Y1; Y2; d) denote a 1    pointwise upper condence bound on the dierence curve
m2(#2; d)  m1(#1; d), i.e. P fm2(#2; d) m1(#1; d)  U (Y1; Y2; d)g  1    for all d 2 D,
where  denotes the pre-specied signicance level and Y` the vector of observations from
group ` = 1; 2. Similarly, let L (Y1; Y2; d) denote a 1  pointwise lower condence bound on
m2(#2; d) m1(#1; d). Using these pointwise condence bounds we can deduce a condence
interval for the maximum absolute dierence between the two models maxd2D jm2(#2; d)  
m1(#1; d)j over the region D, that is
P

max
d2D
jm2(#2; d) m1(#1; d)j  max

max
d2D
U (Y1; Y2; d) ; min
d2D
L (Y1; Y2; d)
	  1  :
(2)
The proof is given in Appendix A. For moderate sample sizes the pointwise condence bounds
U (Y1; Y2; d) and L (Y1; Y2; d) can be derived from the delta method (9). Let u1  denote the
1   quantile of the standard normal distribution. Then,
U (Y1; Y2; d) = m2(#^2; d) m1(#^1; d) + u1 ^(d)
and
L (Y1; Y2; d) = m2(#^2; d) m1(#^1; d)  u1 ^(d)
are the desired 1  asymptotic pointwise upper and lower condence bounds, respectively,
for m2(#2; d) m1(#1; d). Here, #^` denotes the least squares estimate of #` and
^2(d) =
^21
n1
 
@
@#1
m1(#^1; d)
T
^ 11
 
@
@#1
m1(#^1; d)

+
^22
n2
 
@
@#2
m2(#^2; d)
T
^ 12
 
@
@#2
m2(#^2; d)

(3)
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is an estimate of the variance of m2(#^2; d)  m1(#^1; d). In (3) ^2` , is the common variance
estimate in the `th group (` = 1; 2) and ^` =
Pk`
i=1
n`;i
n`
@
@#`
m`(x`;i;; #^`)
 
@
@#`
m`(x`;i;; #^`)
T
.
Note that the matrix
^2`
n`
^ 1` is a consistent estimator of the covariance matrix of #^` (` = 1; 2).
Next we are interested in demonstrating that the maximum absolute dierence in response
between the two regression models in (1) over the covariate space D is not larger than a
pre-specied margin  > 0. Formally, we test the null hypothesis
H : max
d2D
jm2(#2; d) m1(#1; d)j   (4)
against the alternative hypothesis
K : max
d2D
jm2(#2; d) m1(#1; d)j < : (5)
Consequently, using the condence interval (2), equivalence is claimed if
max

max
d2D
U (Y1; Y2; d) ; min
d2D
L (Y1; Y2; d)
	
< :
Thus, we reject the null hypothesis H at level  and assume similarity of m1 and m2 if
  < min
d2D
L (Y1; Y2; d) and max
d2D
U (Y1; Y2; d) < : (6)
2.2 Case study
To illustrate the methodology described in Section 2.1, we consider a dose nding trial for
a weight loss drug given to patients suering from overweight or obesity. This trial aims at
comparing the dose response relationship for two regimens, namely a once-daily (o.d.) and
a twice-daily (b.i.d.) application of the drug. The primary objective in this trial is not to
apply a joint model that includes both regimen, but rather treat both regimen separately
and assess the similarity of dose response. Because this study has not been completed yet, we
simulate data based on the assumptions made at the trial design stage. For condentiality
reasons, we use blinded dose levels and all chosen dose levels denote the total daily dose.
These limitations do not change the utility of the calculations below.
In this trial, the dose levels for the o.d. and b.i.d. regimens are given by 0:033; 0:1; 1 and
0:067; 0:3; 1, respectively. Patients are thus randomized to receive either placebo or one of
the six active treatments. In total, we assume that 350 patients are allocated equally across
the seven arms, resulting in a sample size of 50 patients per treatment group. The primary
endpoint of the study was the percentage of weight loss after a treatment duration of 20
weeks, with smaller values corresponding to a better treatment eect.
We used the nls function in R (10) to compute the non-linear least squares estimates #^` of #`
and the standard errors necessary for calculating U (Y1; Y2; d) and L (Y1; Y2; d) from Section
5
2.1. The R code for this example and all other calculations in this paper is available from
the authors upon request.
For this example, we tted two Emax models: m1(#1; d) = #1;1 + #1;2
d
#1;3+d
for the o.d.
regimen and m2(#2; d) = #2;1 + #2;2
d
#2;3+d
for the b.i.d. regimen, where #1 = (#1;1; #1;2; #1;3)
and #2 = (#2;1; #2;2; #2;3). For the data set at hand, #^1 = (0:03; 5:17; 7:94) and #^2 =
( 0:09; 6:56; 31:24). Figure 2a displays the tted dose response models m1(#^1; d) and
m2(#^2; d), d 2 [0; 1], together with the individual observations, where the y-axis is truncated
to [ 7; 1] for better readability. Figure 2b displays the dierence m2(#^2; d)   m1(#^1; d)
together with the associated 90% pointwise condence intervals for each dose d 2 [0; 1].
The maximum upper condence bound for  = 0:1 is maxd2D U (Y1; Y2; d) = 2:137 at dose
d = 0:08 and the minimum lower condence bound is mind2D L (Y1; Y2; d) =  1:848 at
the maximum dose d = 1. That is, the maximum dierence in response between the two
regimens over the dose range D = [0; 1] lies between  1:848 and 2:137. Therefore, similarity
of the dose response curves can be claimed at level  = 0:1 as long as  is larger than 2:137,
according to (6).
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Figure 2: Plots for the weight loss case study. (a) The tted Emax model m1 (m2) for the
o.d. (b.i.d.) regimen is given by the solid (dashed) line with observations marked by \x"
(\o"). (b) Mean dierence curve with associated pointwise 90% condence bounds. Bold
dots denote the maximum upper and minimum lower condence bound over D = [0; 1].
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2.3 Simulations
We conducted a simulation study to investigate the operating characteristics of the method
described in Section 2.1. We investigated coverage probabilities of the condence intervals
as well as Type I error rates and power of the test (6) for dierent scenarios. To simplify
the simulations, we assumed balanced designs and that dose is the only covariate. For all
simulations below, we generated data as follows:
Step 1: Specify the models m1;m2, their parameters #1; #2, a common variance 
2 and the
actual dose levels d`;i.
Step 2: Generate n`;i values m`(#`; d`;i) at each dose d`;i.
Step 3: Generate normally distributed residual errors "`;i;j  N(0; 2) and use the nal
response data
Y`;i;j = m`(#`; d`;i) + "`;i;j; j = 1; : : : ; n`;i; i = 1; : : : k`; ` = 1; 2: (7)
This procedure is repeated using 10; 000 simulation runs.
2.3.1 Coverage probabilities
In the following we report the coverage probabilities of the condence intervals for the
maximum absolute dierence derived in (2) under two dierent scenarios.
Scenario 1 We start with the comparison of a linear and a quadratic model. More specif-
ically, we chose the linear model m1(d) = d and the quadratic model m2(d) = 31 + (1  
41)d + 1d
2, d 2 [1; 3]; see Figure 3a for 1 = 1. We assumed identical dose levels d`;i = i,
i = 1; 2; 3 for both regression models ` = 1; 2. Consequently, the two curves coincide at
the two boundary doses d = 1; 3, and the maximum dierence 1 occurs at dose d = 2.
For each conguration of 2 = 1; 2; 3 and 1 = 1; 2; 3 we used (7) to simulate n`;i = 10(50)
observations at each dose level d`;i, resulting in n` = 30(150), ` = 1; 2.
The left side of Table 1 displays the coverage probabilities for  = 0:05; 0:1. We observe
that the nominal level of 1    is reached in all cases under consideration, which conrms
(2). The condence intervals are more accurate for larger sample sizes and smaller variances,
because we used the asymptotic quantiles from the normal distribution. If, instead, we select
the quantiles from the t distribution, the simulated coverage probabilities are closer to the
nominal 1    level (results not shown here). Note that the condence bounds perform
better for larger values of 1. This eect can be explained by a careful look at the proof
given in Appendix A and the particular example under consideration. First note that the
maximum absolute dierence 1 between the two curves is attained at a single point, say
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Figure 3: Graphical illustration of the two scenarios used for the simulations. Open dots
in the left panel indicate the actual dose levels. In the right panel they indicate the doses
where the maximum distance to the reference curve m1 (dashed line) is observed.
d0; see Figure 3a. If this dierence is large then either maxd2D U (Y1; Y2; d) = U (Y1; Y2; d0)
or  mind2D L (Y1; Y2; d) = L (Y1; Y2; d0) with high probability and consequently there is
equality either in (16) or (17) in Appendix A. The same eect appears for increasing sample
sizes and smaller values of 1 as in this case the parameter estimates and approximation of
the coverage probability of the condence interval are more precise.
Scenario 2 We now consider the comparison of two dierent Emax models, where the
maximum distances with respect to the same reference model are 0:25; 0:5; 1; 1:5 and 2.
More specically, we compared the reference Emax model m1(d) = 1 +
9:70d
6:70+d
with
m12(d) = 1+
6:88d
3:60 + d
; m22(d) = 1+
5:66d
2:25 + d
; m32(d) = 1+
4:52d
1 + d
; m42(d) = 1+
4:05d
0:48 + d
; m52(d) = 1+
3:82d
0:22 + d
;
(8)
where the dose range is given by D = [0; 4]. Note that the placebo response at d = 0 is 1 and
the response at the highest dose d = 4 is 4:62 for all ve models; see Figure 3b. The dierence
curve is given bymh2(#
h
2 ; d) m1(#1; d) for h = 1; 2; 3; 4; 5. Note that the dose which produces
the maximum dierence is dierent for each h. More precisely, these doses are given by
1:4; 1:28; 1:04; 0:82 and 0:61 for h = 1; : : : ; 5; see again Figure 3b. The maximum absolute
distance attained at each of these doses is denoted by 1 = maxd2D
mh2(#h2 ; d) m1(#1; d).
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Coverage probabilities Type I error rates
 = 0:05  = 0:1  = 0:05  = 0:1
1 
2 n` = 30 n` = 150 n` = 30 n` = 150 n` = 30 n` = 150 n` = 30 n` = 150
1 1 0.987 0.950 0.953 0.906 0.012 0.050 0.046 0.095
1 2 0.999 0.956 0.991 0.906 0.001 0.042 0.009 0.088
1 3 1.000 0.971 0.999 0.923 0.000 0.031 0.001 0.077
2 1 0.949 0.952 0.901 0.907 0.047 0.049 0.096 0.105
2 2 0.960 0.951 0.913 0.901 0.039 0.048 0.079 0.095
2 3 0.977 0.950 0.936 0.902 0.025 0.047 0.065 0.097
3 1 0.951 0.954 0.906 0.908 0.053 0.048 0.102 0.100
3 2 0.952 0.954 0.905 0.907 0.048 0.047 0.094 0.099
3 3 0.949 0.952 0.900 0.903 0.052 0.049 0.098 0.099
Table 1: Simulated coverage probabilities and Type I error rates for dierent congurations
of 1, 
2, , and n` under Scenario 1.
We assumed identical dose levels d`;i = i   1, i = 1; 2; 3; 4; 5 for both regression models
` = 1; 2. For each conguration of 2 = 1; 2; 3 and 1 = 0:25; 0:5; 1; 1:5; 2, we used (7) to
simulate n`;i = 30 observations at each dose level d`;i, resulting in n` = 150, ` = 1; 2.
The left side of Table 2 displays the coverage probabilities for  = 0:05; 0:1. As already
seen under Scenario 1, the condence intervals are more accurate for smaller variances (and
larger sample sizes, results not shown here) and for increasing values of 1. As before,
asymptotically the coverage probability is at least 1  under all congurations investigated
here.
2.3.2 Type 1 error rates
For the Type I error rate simulations we investigated the two scenarios from Figure 3 for
each conguration of  = 0:05; 0:1 and 2 = 1; 2; 3. Further, we set  = 1 in (4). For
a xed conguration, we generated data according to (7), t both models, performed the
hypothesis test (6) and counted the proportion of rejecting the null hypothesis H. Note that
due to the choice of  both Scenarios 1 and 2 belong to the null hypothesis H dened in (4).
Thus, rejecting H would be a Type I error, i.e. we would erroneously claim similarity of the
two dose response curves.
The right side of Table 1 displays the simulated Type I error rates under Scenario 1. We
observe that the simulated Type I error rate is bounded by the nominal signicance level
 for all congurations investigated here, indicating that the hypothesis test (6) is indeed
a level- test, even under total sample sizes as small as 30. Note also that the signicance
level is actually well exhausted under many congurations. For small sample sizes and
small values of  the test becomes conservative, matching the observed performance of the
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Coverage probabilities Type I error rates
(m1;m2) 1 2  = 0:05  = 0:1  = 0:05  = 0:1
(m1;m
1
2) 0.25 1 1.000 1.000 0.000 0.000
2 1.000 1.000 0.000 0.000
3 1.000 1.000 0.000 0.000
(m1;m
2
2) 0.5 1 0.994 0.960 0.006 0.040
2 1.000 0.993 0.000 0.007
3 1.000 1.000 0.000 0.000
(m1;m
3
2) 1 1 0.954 0.893 0.036 0.107
2 0.963 0.903 0.047 0.097
3 0.983 0.942 0.015 0.058
(m1;m
4
2) 1.5 1 0.952 0.899 0.048 0.101
2 0.962 0.913 0.038 0.087
3 0.949 0.897 0.051 0.103
(m1;m
5
2) 2 1 0.945 0.902 0.055 0.098
2 0.942 0.889 0.068 0.118
3 0.941 0.896 0.065 0.116
Table 2: Simulated coverage probabilities and Type I error rates for dierent model choices
and congurations of 2 and  under Scenario 2, for n` = 150; ` = 1; 2.
condence bounds shown in the left side of Table 1. Again, this conservatism disappears for
large sample sizes.
The right side of Table 2 displays the simulated Type I error rates under Scenario 2. As
before, the simulated Type I error rate is bounded by the nominal signicance level  under
all congurations. However, we observe that the test is very conservative for small values of
1, as already expected from the previously reported results on the coverage probabilities.
2.3.3 Power
We now consider testing the null hypothesis H in (4) for  = 1, where in fact the maximum
dierence is smaller than 1. We start with the comparison of the models from Scenario 1 for
dierent values of 1 under the alternative; see Figure 4. The dose levels remain the same
as under Scenario 1. For each conguration of 2 = 1; 2; 3 and 1 = 0; 0:25; 0:5; 0:75; 0:9, we
used (7) to simulate n = 10(30; 50) observations under m1 and m2 at each dose level d`;i,
resulting in n` = 30(90; 150), ` = 1; 2. Table 3 summarizes the results for  = 0:05; 0:1. The
power increases with decreasing values of 1. For large values of 
2 the power remains small,
even for 1 = 0. In these cases we need larger sample sizes n` in order to achieve reliable
10
results, as otherwise, due to the large variances, the condence intervals in (2) become too
wide and hence the test very conservative.
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Figure 4: Graphical illustration of Scenario 1 used for the power simulations. Open dots
indicate the actual dose levels.
Regarding Scenario 2, we tested the null hypothesis H in (4) using  = 1 and generating
data under the models m1, m
1
2 and m
2
2 dened in (8). Hence we simulated the performance
of the test under the alternative K in (5) for dierent choices of  and . For the sake of
brevity we restrict ourselves again to a xed total sample size of n` = 150, ` = 1; 2. Table 4
displays the simulated power. We observe that the test achieves high power, even for larger
variances. However, the power decreases for an increasing true maximum distance between
the models and for increasing variances.
2.4 Placebo-adjusted modeling
So far we assessed the similarity of two dose response models in terms of the maximum
dierence over the dose range under investigation. Sometimes one might be interested in
adjusting for the placebo response, that is, the treatment eect relative to the placebo
response, before comparing two dose response curves. In this case one has to modify the
results from Section 2.1 as follows. Dierent to model (1), we consider the placebo-adjusted
responses
Y`;i;j = m` (#`; d`;i) m` (#`; 0) + "`;i;j; j = 1; : : : ; n`;i; i = 1; : : : k`; ` = 1; 2; d`;i 2 D:
11
 = 0:05  = 0:1
1 
2 n` = 30 n` = 90 n` = 150 n` = 30 n` = 90 n` = 150
0.00 1 0.211 0.966 0.999 0.426 0.988 0.999
0.25 1 0.170 0.939 0.997 0.377 0.974 0.999
0.50 1 0.102 0.731 0.917 0.268 0.843 0.958
0.75 1 0.046 0.306 0.444 0.143 0.433 0.583
0.90 1 0.023 0.111 0.144 0.074 0.195 0.245
0.00 2 0.002 0.544 0.911 0.046 0.749 0.967
0.25 2 0.001 0.479 0.867 0.045 0.692 0.941
0.50 2 0.001 0.302 0.628 0.030 0.500 0.770
0.75 2 0.000 0.119 0.247 0.012 0.245 0.391
0.90 2 0.000 0.050 0.098 0.011 0.128 0.181
0.00 3 0.000 0.196 0.651 0.007 0.434 0.822
0.25 3 0.000 0.162 0.576 0.005 0.382 0.758
0.50 3 0.000 0.098 0.365 0.004 0.263 0.558
0.75 3 0.000 0.040 0.142 0.002 0.128 0.276
0.90 3 0.000 0.021 0.050 0.001 0.072 0.126
Table 3: Simulated power for  = 1 and dierent congurations of 1, 
2, , and n` in
Scenario 1.
(m1;m2) 1 2  = 0:05  = 0:1
(m1;m1) 0 1 0.986 0.996
(m1;m
1
2) 0.25 1 0.980 0.992
(m1;m
2
2) 0.5 1 0.871 0.938
(m1;m1) 0 2 0.719 0.873
(m1;m
1
2) 0.25 2 0.657 0.833
(m1;m
2
2) 0.5 2 0.442 0.655
(m1;m1) 0 3 0.350 0.622
(m1;m
1
2) 0.25 3 0.286 0.553
(m1;m
2
2) 0.5 3 0.183 0.400
Table 4: Simulated power for dierent model choices and congurations of 2 and  under
Scenario 2, for  = 1 and n` = 150, l = 1; 2.
The condence interval for the maximum absolute dierence between the placebo-adjusted
curves is then given by
P

max
d2D
j(m2(#2; d) m2(#2; 0))  (m1(#1; d) m1(#1; 0))j  max

max
d2D
U 0 (Y1; Y2; d) ; min
d2D
L0 (Y1; Y2; d)
	
 1  ; 12
where U 0 (Y1; Y2; d) and L0 (Y1; Y2; d) denote the pointwise condence bounds for the placebo-
adjusted dierences derived by the delta method. For example,
U 0 (Y1; Y2; d) = (m2(#^2; d) m2(#^2; 0))  (m1(#^1; d) m1(#^1; 0)) + u1 ^0(d);
where ^0(d) is calculated for the dierence of two placebo-adjusted dose response curves.
Proceeding, the null hypothesis of interest becomes
H 0 : max
d2D
j(m2(#2; d) m2(#2; 0))  (m1(#1; d) m1(#1; 0))j  
and following (6) we reject H 0 if
  < min
d2D
L0 (Y1; Y2; d) and max
d2D
U 0 (Y1; Y2; d) < : (9)
To illustrate this methodology, we revisit the weight loss case study from Section 2.2. The
individual model ts remain the same, i.e. m1(#1; d) = 0:03 5:17 d7:94+d for the o.d. regimen
and m2(#2; d) =  0:09  6:56 d31:24+d for the b.i.d. regimen. Figure 5a displays the placebo-
adjusted model ts m1(#^1; d) m1(#^1; 0) and m2(#^2; d) m2(#^2; 0), d 2 [0; 1], together with
the individual observations, where only the range [ 7; 1] is displayed on the vertical axis for
better readability. Figure 5b displays the dierence (m2(#^2; d)  m2(#^2; 0))   (m1(#^1; d)  
m1(#^1; 0)) together with the associated 90% pointwise condence intervals for each dose
d 2 [0; 1]. In this example, the estimated placebo eects are very similar compared with the
original ts. Thus, the placebo-adjusted dierence curve and its condence bounds do not
change much compared with the previous results of Section 2:2; see Figure 2. The maximum
upper condence bound for  = 0:1 is maxd2D U 0 (Y1; Y2; d) = 2:255, again observed at dose
d = 0:08, and the minimum lower condence bound is mind2D L0 (Y1; Y2; d) =  1:730 at
dose d = 1. That is, the maximum placebo-adjusted dierence between the two regimens
over the dose range D = [0; 1] lies between  1:730 and 2:255. Therefore, similarity of the
placebo-adjusted dose response curves can be claimed according to (9) as long as  is larger
than 2:255.
3 Assessing the similarity of two target doses
This section focuses on assessing the similarity of two target doses. We consider the dierence
between the minimum eective doses (MEDs) of two dose response curves from two non-
overlapping subgroups. We derive condence intervals and statistical tests to decide at a
given level  whether the absolute dierence of two MEDs is smaller than a prespecied
margin . Furthermore, we illustrate the proposed methodology by revisiting the case study
from 2.2 and investigate its operating characteristics.
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Figure 5: Placebo-adjusted plots for the weight loss case study. (a) The placebo-adjusted
Emax model t m1 (m2) for the o.d. (b.i.d.) regimen is given by the solid (dashed) line with
observations marked by \x" (\o"). (b) Mean dierence curve with associated pointwise 90%
condence bounds. Bold dots denote the maximum upper and minimum lower condence
bound over D = [0; 1].
3.1 Methodology
Following (1), the MED is dened as the smallest dose that produces a clinically relevant
response  on top of the placebo eect (i.e. at dose d = 0). That is,
MED` =MED`(#`) = inf
d2D
fm`(#`; 0) < m`(#`; d) g ; ` = 1; 2: (10)
From now on we assume strict monotonicity of the dose response curves m` such that (10)
becomes
MED` =MED`(#`) = m
 1
` (#`;m`(#`; 0) + ); ` = 1; 2;
where the inverse is calculated with respect to d for xed model parameters #1 and #2.
Estimates for the MED are then given by
\MED` = m 1` (#^`;m`(#^`; 0) + ); ` = 1; 2;
where #^1 and #^2 are the non-linear least squares estimators for the true parameters. Due to
the asymptotic normality of the estimates #^1 and #^2, the estimated dierence of the MEDs
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is approximately normal distributed (11). To be more precise, the delta method (12) gives
\MED1  \MED2   (MED1  MED2)  N (0;  2); (11)
for
 2 =

@
@#1
m 11 (#1;1)
T
21
n1
 11
@
@#1
m 11 (#1;1) +

@
@#2
m 12 (#2;2)
T
22
n2
 12
@
@#2
m 12 (#2;2)
and ` = m`(#`; 0) + ; ` = 1; 2. The variance 
2 can be estimated by replacing #` and
` by their estimates #^` and ^`, ` = 1; 2; see Section 2.1. The corresponding estimator is
denoted by ^ 2. It then follows from (11) that
P
n
MED1  MED2 2
h
\MED1  \MED2   u1 =2^ ;\MED1  \MED2 + u1 =2^
io
n1;n2!1 ! 1  ; (12)
and an asymptotic (1  )-condence interval for the dierence of the MEDs is given by\MED1  \MED2   u1 =2^ ;\MED1  \MED2 + u1 =2^:
In order to derive a test for similarity of two target doses we consider the problem of testing
H 00 : jMED1  MED2j   against K 00 : jMED1  MED2j < : (13)
In Appendix B we show that rejecting H 00 if
j\MED1  \MED2j < c; (14)
gives an asymptotic (uniformly most powerful) level  test, where c is the unique solution
of the equation
 = 

c  
^

  
 c  
^

: (15)
Note that (15) can easily be solved by using Newton's algorithm (13).
3.2 Case study revisited
To illustrate the methodology in the previous subsection, we revisit the weight loss case study
from Section 2.2. Recall the individual model ts m1(#^1; d) = 0:03  5:17 d7:94+d for the o.d.
regimen and m2(#^2; d) =  0:09   6:56 d31:24+d for the b.i.d. regimen. We chose a clinically
relevant dierence of  =  3. That is, a weight loss of 3% compared to the placebo response
is assumed to be a clinically relevant eect on top of the placebo response at dose d = 0.
Therefore,\MED1 = m 11 (#^1; 0:03   3) = 0:073,\MED2 = m 12 (#^2; 0:09   3) = 0:176 and
\MED1 \MED2 =  0:103. Figure 6(a) displays the model ts m`(#^`; d), together with the
estimates\MED`, ` = 1; 2.
The 1    condence interval for the true dierence MED1   MED2 is then given by 0:103  u1 =20:119; 0:103 + u1 =20:119. For example,
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MED1  MED2 2 [ 0:338; 0:133] for  = 0:05 and MED1  MED2 2 [ 0:300; 0:094] for
 = 0:1. Applying the test in (14) for  = 0:05 allows us to claim similarity of the twoMEDs
whenever  > 0:3 as we have for the unique solution of (15) c > 0:103 = j\MED1  \MED2j
in this case. Figure 6(b) displays the value of c as a function of . For  = 0:1 we obtain by
similar calculations that  has to be larger than 0:255 in order to claim similarity.
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Figure 6: Plots for the revisited weight loss case study. (a) The tted Emax model m1 (m2)
for the o.d. (b.i.d.) regimen is given by the solid (dashed) line, together with the estimated
MEDs for  =  3. (b) Plot of the unique solution c of equation (15) as a function of .
The dashed lines indicate the absolute dierence of the MED estimates and the minimum
choice of  in order to claim similarity for  = 0:05.
3.3 Simulations
We now report the results of a simulation study to investigate the operating characteristics
of the method described in Section 3.1. Adapting the data generation algorithm from Sec-
tion 2.3, we investigated the coverage probabilities of the condence intervals in (12) as well
as the Type I error rates and power of the test (14) for dierent scenarios. All results were
obtained using 10; 000 simulation runs.
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Figure 7: Graphical illustration of Scenarios 3 and 4 used for the simulations. (a) displays
the shifted Emax models with 1 = 2. (b) displays the curves for Scenario 4, together with
the MEDs corresponding to  = 1:6.
3.3.1 Coverage probabilities
Scenario 3 We start with the comparison of two shifted Emax models m1(d; #1) = 1 +
5d=(1 + d) and m2(d; #2) = 5d=(1 + d) over D = [0; 4], with identical dose levels d`;i =
i   1; i = 1; : : : ; 5 for both regression models ` = 1; 2; see Figure 7a. Because the models
are shifted by the constant 1, the true dierence MED1  MED2 = 0 regardless of the
value for . For each conguration of 2 = 1; 2 and 1 = 1; 2; 3 we used (7) to simulate
n`;i = 6(30) observations at each dose level d`;i, resulting in n` = 30(150), ` = 1; 2.
The left side of Table 5 displays the coverage probabilities for  = 0:05; 0:1. We observe that
the coverage probability is at least 1  under all congurations. The condence intervals are
more accurate for larger sample sizes and smaller variances, which conrms the asymptotic
result from (12). Furthermore, the simulated dierences between the MED estimates are
very close to the true dierence under all congurations (results not shown here).
Scenario 4 We now consider the comparison of the Emax model m1(d; #1) = 1+4d=(2+d)
with the linear model m2(d; #2) = 1 + 0:8d for the same set of doses as in Scenario 3. Note
that the responses at doses d = 0 and d = 3 are the same in both models; see Figure 7b.
For each conguration of 2 = 1; 2; 3 and  = 0:8; 1:6; 2:4, we used again (7) to simulate
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Coverage probabilities Type I error rates
 = 0:05  = 0:1  = 0:05  = 0:1
1 
2 n` = 30 n` = 150 n` = 30 n` = 150 n` = 30 n` = 150 n` = 30 n` = 150
1 1 0.979 0.959 0.941 0.907 0.050 0.050 0.103 0.103
2 1 0.982 0.958 0.945 0.909 0.053 0.048 0.105 0.105
3 1 0.980 0.961 0.946 0.908 0.053 0.052 0.099 0.105
1 2 0.996 0.967 0.977 0.917 0.049 0.051 0.104 0.101
2 2 0.996 0.968 0.978 0.922 0.052 0.049 0.103 0.101
3 2 0.995 0.966 0.976 0.916 0.045 0.049 0.100 0.099
Table 5: Simulated coverage probabilities and Type I error rates for dierent congurations
of 1, 
2, , and n` under Scenario 3.
n`;i = 6(30) observations at each dose level d`;i, resulting in n` = 30(150), ` = 1; 2.
The left side of Table 6 displays the coverage probabilities for  = 0:05; 0:1. As before,
asymptotically the coverage probability is at least 1  under all congurations investigated
here, except for small sample sizes and  = 2:4 (in which case the MEDs coincide). This
is a direct consequence of the denition of the MED. Inverting an Emax model m(#; d) =
y = #1 + #2d=(#3 + d) gives m
 1
1 (#; y) = #3(y   #1)=(#1 + #3   y). Therefore higher values
of  result in being closer to the pole of m 1, which is at #1+#2 = 5 in this case. However,
further simulations show that the results get better for larger sample sizes and the coverage
probabilities converge quickly to their nominal values. Finally, the simulated dierences
between the MED estimates are very close to the true dierence under all congurations,
except in the case where the MEDs coincide (i.e.  = 2:4; results not shown here).
Coverage probabilities Type I error rates
 = 0:05  = 0:1  = 0:05  = 0:1
 2 n` = 30 n` = 150 n` = 30 n` = 150 n` = 30 n` = 150 n` = 30 n` = 150
0.8 1 0.964 0.965 0.929 0.908 0.036 0.025 0.077 0.068
1.6 1 0.953 0.946 0.922 0.903 0.051 0.040 0.098 0.087
2.4 1 0.920 0.949 0.877 0.916 0.069 0.057 0.137 0.116
0.8 2 0.989 0.968 0.960 0.928 0.050 0.026 0.101 0.061
1.6 2 0.967 0.956 0.936 0.913 0.053 0.045 0.111 0.088
2.4 2 0.918 0.932 0.870 0.901 0.069 0.060 0.143 0.124
Table 6: Simulated coverage probabilities and Type I error rates for dierent congurations
of , 2, , and n` under Scenario 4.
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3.3.2 Type 1 error rates
For the Type I error rate simulations we investigated the two scenarios from Figure 7.
We start with Scenario 3. Because jMED1   MED2j = 0 for all values of , we chose
 = 0. For a xed conguration of parameters, we generated data according to (7), t both
models, performed the hypothesis test (14) and counted the proportion of rejecting the null
hypothesis H 00. The right side of Table 5 displays the simulated Type I error rates under
Scenario 3. We observe that the simulated Type I error rate is well exhausted at the nominal
signicance level  for all congurations investigated here, indicating that the hypothesis
test (14) is indeed a level- test, even under total sample sizes as small as 30.
The right side of Table 6 displays the simulated Type I error rates under Scenario 4. As
before, the simulated Type I error rate is bounded by the nominal signicance level  under
almost all congurations. The test can be liberal for small sample sizes and large values of
, matching the observed performance of the condence bounds shown in the left side of
Table 6. Again, this size ination disappears for large sample sizes.
3.3.3 Power
For the power simulations we again considered the two scenarios from Figure 7 and start
with Scenario 3. Because jMED1  MED2j = 0 for all values of , the power of the test
depends only on the given threshold . For the concrete simulations, we set  = 1 and used
1 = 1 for convenience. For each conguration of 
2 = 1; 2; 3 and  = 0:1; 0:2; 0:5; 1, we used
(7) to simulate n = 10(30; 50) observations under m1 and m2 at each dose level d`;i, resulting
in n` = 30(90; 150), ` = 1; 2. All congurations belong to the alternative in (13). Table 7
summarizes the results for  = 0:05; 0:1. The power increases with increasing values of .
The power decreases for larger values of 2, especially for small values of . In these cases
we need larger sample sizes n` in order to achieve reliable results.
For the nal set of simulations, we revisit Scenario 4 and investigate the power for dierent
values of 2 and . We set  = 0:8 and n` = 30; 150 for ` = 1; 2 and summarize the results
in Table 8. In alignment with all former results, the performance of the test is worse in case
of  = 2:4 due to the already mentioned numerical problems when calculating the MEDs.
In general, the power increases with increasing sample sizes and decreasing variances under
all observed congurations. The power converges to 1 for n1; n2 !1.
4 Conclusions
The choice of the equivalence margins  and  in (4) and (13), respectively, is a delicate
problem. This choice depends on the particular application and has to be made by clinical
experts, possibly with input from statisticians and other quantitative scientists. Regulatory
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 = 0:05  = 0:1
 2 n` = 30 n` = 90 n` = 150 n` = 30 n` = 90 n` = 150
1 1 0.979 1.000 1.000 0.989 1.000 1.000
0.5 1 0.679 0.988 0.999 0.783 0.995 1.000
0.2 1 0.116 0.364 0.641 0.226 0.543 0.784
0.1 1 0.061 0.086 0.123 0.123 0.179 0.232
1 2 0.823 0.997 1.000 0.893 0.999 1.000
0.5 2 0.400 0.853 0.975 0.524 0.915 0.987
0.2 2 0.078 0.167 0.283 0.163 0.288 0.462
0.1 2 0.055 0.066 0.077 0.109 0.132 0.156
Table 7: Simulated power for dierent congurations of , 2, , and n` in Scenario 3.
 = 0:05  = 0:1
 2 n` = 30 n` = 150 n` = 30 n` = 150
0.4 1 0.914 1.000 0.958 1.000
0.8 1 0.116 0.625 0.261 0.778
1.6 1 0.057 0.080 0.118 0.152
2.4 1 0.090 0.118 0.163 0.233
0.4 2 0.668 0.999 0.806 0.999
0.8 2 0.089 0.324 0.183 0.523
1.6 2 0.058 0.060 0.116 0.122
2.4 2 0.081 0.093 0.165 0.189
Table 8: Simulated power for dierent congurations of , 2, , and n` in Scenario 4.
guidance documents are available in specic settings, such as for the problem of demon-
strating bioequivalence. For example, (14) discusses how the thresholds for bioequivalence
hypotheses of the form considered in this paper can be dened in various settings. For
the comparison of curves as considered in this paper we refer to Appendix 1 of (14), with
emphasis on dissolution proles on the basis of specic measures.
In this paper we investigated the problem of assessing similarity of dose response curves
or target doses for two non-overlapping subgroups of patients for normally distributed re-
sponses. We leave several extensions of this basic problem for further research. For example,
in certain applications it may be necessary to demonstrate similarity of dose response curves
or target doses for more than two non-overlapping subgroups (such as more than two ge-
ographic regions or age classes). Finally, the research of this paper was motivated by the
20
need of comparing the dose response information from males with female or Japanese with
non-Japanese patients. In practice, one may equally be interested in comparing males or
Japanese with the overall population rather than the complementary subgroup. These cases
are more dicult to handle because the data for the specic subgroup of interest is also in-
cluded in the overall population, thus introducing correlations through nested data structure
that need special attention. Again, we leave this topic for future research.
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A. Coverage probability of the condence interval for
the maximum absolute dierence
In the following we prove equation (2) from Section 2.1. To this end, let d0 2 D such that
max
d2D
jm2(#2; d) m1(#1; d)j = jm2(#2; d0) m1(#1; d0)j:
Hence
P = P
n
max
d2D
jm2(#2; d) m1(#1; d)j  max

max
d2D
U (Y1; Y2; d) ; min
d2D
L (Y1; Y2; d)
	o
= P
n
jm2(#2; d0) m1(#1; d0)j  max

max
d2D
U (Y1; Y2; d) ; min
d2D
L (Y1; Y2; d)
	o
 P
n
jm2(#2; d0) m1(#1; d0)j  max

U (Y1; Y2; d0) ; L (Y1; Y2; d0)
	o
:
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Now we distinguish two cases. If m2(#2; d0) m1(#1; d0)  0 we have
P  P
n
m2(#2; d0) m1(#1; d0)  U (Y1; Y2; d0)
o
n1;n2!1 ! 1  ; (16)
as U (Y1; Y2; d) is a 1   pointwise upper condence bound on m2(#2; d) m1(#1; d). Oth-
erwise, m2(#2; d0) m1(#1; d0)  0 and the same argument applies to L (Y1; Y2; d), yielding
P  P
n
m2(#2; d0) m1(#1; d0)  L (Y1; Y2; d0)
o
n1;n2!1 ! 1  : (17)
B. Asymptotic level of the test for similarity of two tar-
get doses
We show that the test (14) dened in Section 3.1 has asymptotic level , that is
lim
n1;n2!1
P

j\MED1  \MED2j  c

  (18)
under the null hypothesis. First note that the solution of equation (15) is unique as the
function c!    c 
^
    c 
^

is strictly increasing with limits  1 and 1 as c!  1 and
1, respectively. Next, let t =MED1 MED2, t^ =\MED1 \MED2 and denote the power
function of the test by
Gn1;n2() = P
 t^ < c :
The assertion (18) is then equivalent to
lim
n1;n2!1
Gn1;n2()   for all jtj  : (19)
A standard calculation shows that
Gn1;n2(t) = P (jt^j  c) = P ( c  t^  c) = P
 c  t
^
 t^  t
^
 c  t
^

n1;n2!1 ! ~G(t) := 
c  t


  
 c  t


Now consider the problem of testing the hypotheses H : jtj   against K : jtj <  for
normally distributed data X  N (t;  2). A simple calculation shows that the (asymptotic)
power function ~G coincides with the power of the test, which rejects the null hypothesis
H : jtj   whenever jXj  c. Considering the discussion in Lehmann et al. (15, p. 81),
it follows that this test is uniformly most powerful and unbiased of size . This implies
~G(t)  ~G() =  for all jtj   and proves (19).
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